Anti-IL-1 molecules: New comers and new indications

Joint Bone Spine

Volumn 77, Issue 2, 2010, Pages 102-107

  Moltó, Anna ^a   Olivé, Alejandro ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Anakinra; Autoinflammatory syndromes; Interleukin 1; Rheumatoid arthritis; Spondyloarthropathy

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

ADULT ONSET STILL DISEASE; ANKYLOSING SPONDYLITIS; AUTOINFLAMMATORY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GOUT; HUMAN; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; PSEUDOGOUT; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; RECEPTORS, INTERLEUKIN-1; RHEUMATIC DISEASES;

EID: 77949571201     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.10.011     Document Type: Short Survey

References (57)

1. Dinarello C.A., and Wolff S.M. The role of interleukin-1 in disease. N Engl J Med 328 (1993) 106-113
2. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
3. Hallegua D.S., and Weisman M.H. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis 61 (2002) 960-967
4. Rivier C., and Rivest S. Mechanisms mediating the effects of cytokines on neuroendocrine functions in the rat. Ciba Found Symp 172 (1993) 204
5. Tatakis D.N. Interleukin-l and bone metabolism: a review. J Peridontol 64 (1993) 416
6. Arend W.P., and Dayer J.M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33 (1990) 305-354
7. Furmanski P., and Johnson C.S. Macrophage control of normal and leukemic erythropoiesis. Identification of the macrophage derived erythroid suppressing activity as interleukin-l and the mediator of its effect as tumor necrosis factor. Blood 75 (1990) 2328
8. Van den Berg W.B. Is there a rationale for combined TNF and IL-1 blocking in arthritis. Clin Exp Rheumatol 20 (2002) 21-25
9. Boissier M.C., Assier E., Falgarone G., et al. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 75 (2008) 373-375
10. Eastgate J.A., Symons J.A., Wood N.C., et al. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2 (1988) 706-708
11. Kahle P., Saal J.G., Schaudt K., et al. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial fluid. Ann Rheum Dis 51 (1992) 731-734
12. Chikanza I.C., Roux-Lombard P., Dayer J.M., et al. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum 38 (1995) 642-648
13. Otani K., Nita I., Macaulay W., et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 156 (1996) 3558
14. Evans C.H., Robbins P.D., Ghivizzani S.C., et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A 102 (2005) 8698
15. Alten R., Gram H., Joosten L.A., et al. The human anti-Il-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 10 (2008) 67
16. Church L.D., and McDermott M.F. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 11 (2009) 81-89
17. Church L.D., and McDermott M.F. Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism. Nat Clin Pract Rheumatol 5 (2009) 14-15
18. Ratner M. IL-1 trap go-ahead. Nat Biotechnol 26 (2008) 485
19. Hoffman H.M., Throne M.L., Amar N.J., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58 (2008) 2443-2452
20. Goldbach-Mansky R., Shroff S.D., Wilson M.A., et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58 (2008) 2432-2442
21. Granowitz E.V., Porat R., Mier J.W., et al. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4 (1992) 353-360
22. Donahue K.E., Gartlehner G., Jonas D.E., et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148 (2008) 124-134
23. Nixon R., Bansback B., and Brennan A. The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology 46 (2007) 1140-1147
24. Lequerré T., Vittecoq O., and le Loët X. What is the role for interleukin-1 receptor antagonist in rheumatic disease?. Joint Bone Spine 74 (2007) 223-226
25. Horai R., Saijo S., and Tanioka H. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191 (2000) 313-320
26. Dinarello C.A. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 343 (2000) 732-734
27. Ghivizzani S.C., Kang R., Georgescu H.I., et al. Constitutive intra-articular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 159 (1997) 3604-3612
28. Koenders M.I., Devesa I., Marijnissen R.J., et al. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 58 (2008) 3461-3470
29. Mariathasan S., and Monack D.M. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7 (2007) 31-40
30. Church L.D., Cook G.P., and McDermot M.F. Primer: inflammasomes and interleukin 1β in inflammatory disorders. Nat Clin Pract Rheumatol 4 (2008) 34-42
31. Stankovic K., and Grateau G. Auto-inflammatory syndromes: diagnosis and treatment. Joint Bone Spine 74 (2007) 544-550
32. Ramos E., Arostegui J.I., Campuzano S., et al. Positive clinical and biochemical responses to anakinra in a 3-year-old patient with cryopyrin-associated periodic syndrome (CAPS). Rheumatology (Oxford) 44 (2005) 1072-1073
33. Hoffman H.M., Rosengren S., Boyle D.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364 (2004) 1779-1785
34. Gerard S., le Goff B., Maugars Y., et al. Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra. Joint Bone Spine 74 (2007) 659
35. Kuijk L.M., Govers A.M., Frenkel J., et al. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66 (2007) 1545-1546
36. Roldan R., Ruiz A.M., Miranda M.D., et al. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 75 (2008) 504-505
37. Klemmer N., Lenain P., Balguerie X., et al. Effectiveness of anti-IL-1 in Schnitzler's syndrome. Joint Bone Spine 74 (2007) 509-510
38. Pascual V., Allantaz F., Arce E., et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201 (2005) 1479-1486
39. Lequerré T., Quartier P., Rosellini D., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67 (2008) 302-308
40. Fitzgerald A.A., Leclercq S.A., Yan A., et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52 (2005) 1794-1803
41. Pétrilli V., and Martinon F. The inflammasome, autoinflammatory diseases, and gout. Joint Bone Spine 74 (2007) 571-576
42. Martinon F., and Glimcher L.H. Gout: new insights into an old disease. J Clin Invest 116 (2006) 2073-2075
43. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9 (2007) 28
44. McGonagle D., Tan A.L., Madden J., et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58 (2008) 631-633
45. Church L.D., Cook G.P., and McDermott M.F. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 4 (2008) 34-42
46. Dougados M., van der Linden S., Leirisalo-Repo M., et al. Sulfasalazine in the treatment of spondyloarthritides. Arthritis Rheum 38 (1995) 618-627
47. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab - a double-blind placebo controlled multicenter trial. Lancet 359 (2002) 1187-1193
48. Davis J.C., Van Der Heijde D., Braun J., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48 (2003) 3230-3236
49. McGarry F., Neilly J., Anderson N., et al. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford) 40 (2001) 1359-1364
50. Tan A.L., Marzo-Ortega H., O'Connor P., et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63 (2004) 1041-1045
51. Blakemore A.I., Tarlow J.K., Cork M.J., et al. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 37 (1994) 1380-1385
52. Suzuki H., Takemura H., and Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus: enhanced production by monocytes and correlation with disease activity. Arthritis Rheum 38 (1995) 1055-1059
53. Moosig F., Zeuner R., Renk C., et al. IL-1RA in refractory systemic lupus erythematosus. Lupus 13 (2004) 605-606
54. Ostendorf B., Iking-Konert C., Kurz K., et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64 (2005) 630-633
55. Son K., Tomita Y., Shimizu T., et al. Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis. Intern Med 39 (2000) 128-135
56. Furlan A., Botsios C., Ruffatti A., et al. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine 75 (2008) 366-367
57. Wendling D., Govindaraju S., Prati C., et al. Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine 75 (2008) 622-624